<SEC-DOCUMENT>0001549595-26-000034.txt : 20260611
<SEC-HEADER>0001549595-26-000034.hdr.sgml : 20260611
<ACCEPTANCE-DATETIME>20260611070657
ACCESSION NUMBER:		0001549595-26-000034
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20260611
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260611
DATE AS OF CHANGE:		20260611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nurix Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001549595
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				270838048
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39398
		FILM NUMBER:		261081428

	BUSINESS ADDRESS:	
		STREET 1:		1600 SIERRA POINT PKWY
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		(415) 660-5320

	MAIL ADDRESS:	
		STREET 1:		1600 SIERRA POINT PKWY
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nurix, Inc.
		DATE OF NAME CHANGE:	20120509
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nrix-20260611.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e93dd-9df4-7ceb-bad7-ea6fc01227ad,g:c9bf44e4-734f-475a-b704-b8eaac39f9a6,d:567261ab541f4b57acb920ef0b9f2372-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nrix-20260611</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-20">0001549595</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-21">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-month-day-year" id="f-22">06/11/2026</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-23">1600 Sierra Point Parkway</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-24">Brisbane</ix:nonNumeric><ix:nonNumeric contextRef="c-1" xsi:nil="true" name="dei:EntityAddressAddressLine2" id="f-25"></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-26">California</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nrix-20260611.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001549595</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-06-11</xbrli:startDate><xbrli:endDate>2026-06-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i567261ab541f4b57acb920ef0b9f2372_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="margin-top:14pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of Earliest Event Reported):&#160;June&#160;11, 2026</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-2">NURIX THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-3">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-4">001-39398</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-5">27-0838048</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(State or Other Jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">of Incorporation or Organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-6">1600 Sierra Point Parkway</ix:nonNumeric>,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-7">Brisbane</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-8">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-9">94005</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-10">415</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-11">660-5320</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">___________________________________________</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-12">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-13">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Trading symbol(s)</span></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">NRIX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#211d1e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:5pt"><span style="color:#211d1e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#211d1e;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-19">o</ix:nonNumeric></span></div><div style="margin-top:5pt"><span style="color:#211d1e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#211d1e;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i567261ab541f4b57acb920ef0b9f2372_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.01&#160;&#160;&#160;&#160;Regulation FD Disclosure.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;11, 2026, Nurix Therapeutics, Inc. (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) issued a press release announcing the presentation at the European Hematology Association Congress (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EHA2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of updated clinical data from from the Phase 1a/1b study of the Company&#8217;s novel Bruton's tyrosine kinase (BTK) degrader bexobrutideg (NX-5948) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the press release, which includes the data to be presented at EHA2026, is attached hereto as Exhibit&#160;99.1 and is incorporated herein by reference.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. In addition, the information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K.</span></div><div><span><br/></span></div><div id="i567261ab541f4b57acb920ef0b9f2372_96"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.01&#160;&#160;&#160;&#160;Other Events.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;11, 2026, the Company announced updated data from the Phase 1 clinical trial of bexobrutideg (NX-5948).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The updated data from the Phase 1a/1b study of bexobrutideg (NX-5948-301) in patients with CLL and SLL include safety findings across all CLL/SLL patients, updated safety findings for patients treated at the recommended Phase&#160;2 dose (RP2D) of 600 mg once daily, updated Phase 1a results with extended follow-up, and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">new</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> data from two Phase&#160;1b cohorts evaluating bexobrutideg in earlier lines of treatment, including a cohort of BTK inhibitor (BTKi)-treated and BCL-2 inhibitor (BCL2i)-na&#239;ve patients and a cohort of BTKi-na&#239;ve patients, including treatment-na&#239;ve patients. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Phase 1a/1b safety findings and Phase 1a demographics</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of the January 1, 2026 data cutoff, the Phase 1a/1b safety population included 142 patients with CLL/SLL, including 86 patients treated at the 600 mg dose. Bexobrutideg was well tolerated across the Phase 1a/1b population, consistent with prior disclosures. The treatment-emergent adverse event (TEAE) profile was comparable between the overall patient population and patients receiving the 600 mg dose, with the most common TEAEs in patients including purpura/contusion, neutropenia, petechiae, diarrhea and fatigue. There were no dose-limiting toxicities. Three Grade 5 adverse events were reported, all of which were deemed not related to treatment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Phase 1a population had received a median of four prior lines of therapy (range = 2-12), including prior BTK inhibitors (97.9%), prior BCL2 inhibitors (83.3%) and prior non-covalent BTK inhibitors (27.1%). At baseline, many patients had mutations associated with BTK inhibitor resistance, including mutations in BTK (38.3%) and PLCG2 (14.9%). Poor prognostic features were common, including TP53 mutations (44.7%). Five patients (10.4%) in the Phase 1a population had central nervous system (CNS) involvement at baseline.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Phase 1a efficacy update</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The updated Phase 1a data included 48 patients with relapsed or refractory CLL/SLL treated at starting dose levels ranging from 50 mg to 600 mg once daily, with a median follow-up of 22.4 months. Among the 47 response-evaluable patients, the objective response rate (ORR) was 83.0%, including two patients (4.3%) with a complete response, one patient (2.1%) with nodal partial response, and 36 patients (76.6%) with partial response.  Six patients (12.8%) showed stable disease and two patients (4.3%) experienced progressive disease. Median progression-free survival was 22.1 months (95% Confidence Interval: 14.0 months to Not Reached). Clinical responses were observed across difficult-to-treat subgroups, including patients with BTK inhibitor resistance mutations, high-risk molecular features and CNS involvement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Phase 1b earlier-line cohorts</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Phase 1b earlier-line cohorts include Cohort 5, which enrolled BTKi-treated and BCL2i-na&#239;ve patients, and Cohort 15, which enrolled BTKi-na&#239;ve patients, including treatment-na&#239;ve patients. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Cohort 5 enrolled 19 patients, 18 of whom remained on treatment as of the data cutoff. Among the 14 patients evaluable for response, the ORR was 92.9% with a median follow-up of 5.2 months.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Cohort 15 enrolled 20 patients, including 10 treatment-na&#239;ve patients, 19 of whom remained on treatment as of the data cutoff. Among the 19 patients evaluable for response, the ORR was 84.2% with a median follow-up of 4.9 months.</span></div><div><span><br/></span></div><div id="i567261ab541f4b57acb920ef0b9f2372_13"></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Exhibits</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed or furnished, as applicable, herewith and this list is intended to constitute the exhibit index:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Title or Description</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex991_nurixpressrelease202.htm">Nurix Therapeutics, Inc. Press Release</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> dated June&#160;11, 2026 </span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i567261ab541f4b57acb920ef0b9f2372_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NURIX THERAPEUTICS, INC.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date: June&#160;11, 2026</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Christine Ring</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Christine Ring, Ph.D., J.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chief Legal Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991_nurixpressrelease202.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i8df873bd269a4bcca83d551b85fc3380_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 99.1</font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Nurix Logo&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Nurix Therapeutics to Report Updated Phase 1a&#47;b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed&#47;Refractory CLL&#47;SLL and Promising Activity in Earlier Lines of Therapy </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Updated Phase 1a data further supports a median progression-free survival of 22.1 months and an objective response rate of 83% in heavily pretreated relapsed&#47;refractory CLL&#47;SLL patients</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Bexobrutideg was well tolerated with longer follow-up demonstrating a safety profile consistent with prior disclosures </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Responses observed across difficult-to-treat patient subgroups, including high-risk features, BTK resistance mutations and CNS involvement</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Data to be presented at the 2026 European Hematology Association (EHA) Congress</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BRISBANE, Calif., June 11, 2026 (GLOBE NEWSWIRE) --</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Nurix Therapeutics, Inc. (Nasdaq&#58; NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced updated clinical data from the Company&#8217;s ongoing NX-5948-301 Phase 1a&#47;b clinical trial evaluating bexobrutideg (NX-5948), an investigational oral CNS-penetrant BTK degrader, in patients with chronic lymphocytic leukemia (CLL). The data will be presented during an oral presentation at the 2026 EHA Congress taking place June 11&#8211;14, 2026, in Stockholm, Sweden.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;These updated data continue to demonstrate the differentiated profile of bexobrutideg, including durable responses in heavily pretreated patients and encouraging activity in patients earlier in their treatment journey,&#8221; said Talha Munir, M.B. Ch.B., Ph.D., consultant hematologist at Leeds Teaching Hospitals NHS Trust and deputy chair of the United Kingdom National Cancer Research Institute CLL Study Group. &#8220;Importantly, responses were observed across patients with difficult-to-treat disease characteristics, including BTK inhibitor resistance mutations, high-risk molecular features and CNS involvement, while maintaining a favorable tolerability profile.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;With longer follow-up in relapsed&#47;refractory CLL and expansion into earlier-line treatment settings, we continue to see a consistent efficacy and safety profile for bexobrutideg,&#8221; said Paula O&#8217;Connor, M.D., chief medical officer of Nurix. &#8220;The durability of responses observed in heavily pretreated patients together with the promising activity seen in BCL2i-na&#239;ve and BTKi-na&#239;ve patients further support the broad potential of BTK degradation across all lines of therapy in CLL.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;These latest findings continue to reinforce our belief that bexobrutideg has the potential to redefine BTK-directed therapy and emerge as a potentially best-in-class treatment for CLL,&#8221; said </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix Therapeutics. &#8220;The updated data to be presented at EHA across Phase 1 cohorts continue to support the launch of a broad Phase 3 monotherapy program and strengthen the rationale for exploring the use of combination regimens in first- and second-line patients. We look forward to advancing these programs through our recently announced collaboration with Roche.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Growing Safety Cohort Continues to Support Differentiated Profile</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Across all Phase 1a&#47;b CLL patients (n&#61;142), bexobrutideg was well tolerated, consistent with prior disclosures, with safety findings generally comparable between patients treated at the 600 mg RP2D and the broader study population.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As of the January 1, 2026, data cutoff&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">No dose-limiting toxicities were observed</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">No treatment-related Grade 5 adverse events were reported</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Treatment discontinuations due to adverse events occurred in only 5.6% of patients</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">The most common treatment-emergent adverse events included purpura&#47;contusion, neutropenia, petechiae, diarrhea, and fatigue. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Updated Phase 1a Data in Relapsed&#47;Refractory CLL Continue to Support Durable Responses</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Phase 1a dose escalation study enrolled 48 patients with relapsed&#47;refractory CLL&#47;SLL treated with bexobrutideg at doses ranging from 50 mg to 600 mg once daily. Patients were heavily pretreated, having received a median of four prior lines of therapy (range 2&#8211;12), including prior BTK inhibitors (97.9%), prior BCL2 inhibitors (83.3%), and prior non-covalent BTK inhibitors (27.1%). Baseline high-risk features included BTK inhibitor resistance mutations (38.3%), TP53 mutations (44.7%), PLCG2 mutations (14.9%), and central nervous system (CNS) involvement (10.4%).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As of the January 1, 2026, data cutoff&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Median follow-up was 22.4 months</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Median progression-free survival (PFS) was 22.1 months (95% CI&#58; 14.0&#8211;NR)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Objective response rate (ORR) was 83.0% (95% CI&#58; 69.2&#8211;92.4)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Responses included two complete responses, one nodal partial response, and 36 partial responses.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Responses were observed across patients with BTK inhibitor resistance mutations, high-risk molecular features, and CNS involvement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Phase 1b Data Supports High ORR in Earlier-Line Cohorts </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nurix also presented new data from two of the Phase 1b cohorts evaluating bexobrutideg in earlier lines of treatment, including patients who had received prior BTKi treatment but were BCL2i-na&#239;ve (Cohort 5) and patients who were BTKi-na&#239;ve, including treatment-na&#239;ve patients (Cohort 15).</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In Cohort 5 (n&#61;19), patients had received prior BTK inhibitor therapy but no prior BCL2 inhibitor&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">ORR was 92.9% (95% CI&#58; 66.1&#8211;99.8) among evaluable patients (n&#61;14)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">18 of 19 patients remained on treatment at data cutoff</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Median follow-up was 5.2 months</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Five patients have not yet reached their first scan but remain on treatment</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In Cohort 15 (n&#61;20), which included BTKi-na&#239;ve and treatment-na&#239;ve patients&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">ORR was 84.2% (95% CI&#58; 60.4&#8211;96.6) among evaluable patients (n&#61;19)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">19 of 20 patients remained on treatment at data cutoff</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Median follow-up was 4.9 months</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Three patients with stable disease remain on treatment</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Bexobrutideg</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant, highly selective small-molecule degrader of Bruton&#8217;s tyrosine kinase (BTK) being developed by Nurix and Roche as a potential best-in-class therapy across oncology, immunology and neurology.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Bexobrutideg is currently being evaluated in the DAYBreak CLL-201 clinical trial (NCT07221500), a pivotal single-arm Phase 2 study in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), and in the NX-5948-301 Phase 1a&#47;1b clinical trial (NCT05131022) in patients with relapsed or refractory B-cell malignancies. A new tablet formulation of bexobrutideg is also being evaluated in a first-in-human single-ascending-dose and multiple-ascending-dose study in healthy volunteers (NCT06717269) to support future development in immunology and neurology indications. Additional information about ongoing clinical trials can be found at clinicaltrials.gov.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Nurix Therapeutics, Inc.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix&#8217;s wholly owned, clinical stage pipeline includes degraders of Bruton&#8217;s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix&#8217;s partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6, SAR448272&#47;NX-3911, in collaboration with Sanofi, a clinical stage degrader of IRAK4, GS6791, in collaboration with Gilead, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix is headquartered in Brisbane, California. For additional information visit </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;www.nurixtx.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#111111;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:134%">This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:134%">the broad potential of BTK degradation in CLL, the therapeutic potential of bexobrutideg, Nurix&#8217;s plans for the development of bexobrutideg, and any plans under and potential benefits of the Nurix-Roche collaboration, </font><font style="background-color:#ffffff;color:#111111;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:134%">are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:134%">Such risks and uncertainties include, among others, (i) the unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development&#59; (ii) whether Nurix will have adequate resources to fund its clinical and commercial obligations under the Nurix-Roche collaboration&#59; (iii) risks and uncertainties related to regulatory review of the Nurix-Roche collaboration, including under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended&#59; and (iv) the risks described under the heading &#8220;Risk Factors&#8221; in Nurix&#8217;s Quarterly Report on Form 10-Q for the period ended February&#160;28,&#160;2026, and subsequent filings with the SEC. </font><font style="background-color:#ffffff;color:#111111;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:134%">Any of these risks and uncertainties could materially and adversely affect Nurix&#8217;s business and results of operations, which could, in turn, have a significant and adverse impact on Nurix&#8217;s stock price. Nurix cautions </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:134%">the reader</font><font style="background-color:#ffffff;color:#111111;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:134%"> not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nurix undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contacts&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Media &#38; Investors&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Kris Fortner&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nurix Therapeutics, Inc.&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Kfortner&#64;nurixtx.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>nrix-20260611.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e93dd-9df4-7ceb-bad7-ea6fc01227ad,g:c9bf44e4-734f-475a-b704-b8eaac39f9a6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nrix="http://www.nurixtx.com/20260611" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.nurixtx.com/20260611">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nrix-20260611_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nrix-20260611_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.nurixtx.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>nrix-20260611_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e93dd-9df4-7ceb-bad7-ea6fc01227ad,g:c9bf44e4-734f-475a-b704-b8eaac39f9a6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_019e93dd-9df4-7ac8-9da7-993a9c6e78c9_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_019e93dd-9df4-73d4-a264-897941afcd8d_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019e93dd-9df4-77ef-91de-e516f7e24f78_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019e93dd-9df4-7e7a-b658-49d7daf1fd56_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_019e93dd-9df4-79a8-afac-80463aa4b3d6_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019e93dd-9df4-7ac4-adfa-cc02511beb44_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019e93dd-9df4-760f-9a75-515da605f8a0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_019e93dd-9df4-746c-83d5-49469caa3c44_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019e93dd-9df4-7f98-916b-aa4ecb4b57c2_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019e93dd-9df4-7c85-bad1-dc992015cf7e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019e93dd-9df4-7e41-bd7d-842eefeb60ed_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019e93dd-9df4-7ec1-a08e-e4764ae4da94_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019e93dd-9df4-721b-8831-b0a27c5fbd0a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019e93dd-9df4-7eee-81e8-eb5492e4a767_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019e93dd-9df4-7161-b375-dcefd7817f31_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019e93dd-9df4-750b-9acb-5c19b005d853_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019e93dd-9df4-7ce6-91f7-a8432334a6b0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019e93dd-9df4-7bc9-9e6c-6d2ddaaca847_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019e93dd-9df4-74d9-b27b-d8a7918fb515_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019e93dd-9df4-723f-9e42-3228bdb8109c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_019e93dd-9df4-740f-94a4-a5be035c5b20_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019e93dd-9df4-7968-83af-87caac5025b0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019e93dd-9df4-72dd-ba47-43180ae78527_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>nrix-20260611_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e93dd-9df4-7ceb-bad7-ea6fc01227ad,g:c9bf44e4-734f-475a-b704-b8eaac39f9a6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nurixtx.com/role/Cover" xlink:type="simple" xlink:href="nrix-20260611.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.nurixtx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019e93dd-9df4-7e2f-9369-a1a99f7f5f6e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_DocumentType_019e93dd-9df4-7e2f-9369-a1a99f7f5f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019e93dd-9df4-7137-865d-dc616e9bc2e6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_DocumentPeriodEndDate_019e93dd-9df4-7137-865d-dc616e9bc2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019e93dd-9df4-706e-bb9b-ff2e6eaaa812" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_EntityRegistrantName_019e93dd-9df4-706e-bb9b-ff2e6eaaa812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019e93dd-9df4-7cac-a9c8-837071c91628" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019e93dd-9df4-7cac-a9c8-837071c91628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019e93dd-9df4-7ba4-927f-f24e7a25c1d5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_EntityFileNumber_019e93dd-9df4-7ba4-927f-f24e7a25c1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019e93dd-9df4-7fdc-8282-c4c585d4d768" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_EntityTaxIdentificationNumber_019e93dd-9df4-7fdc-8282-c4c585d4d768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019e93dd-9df4-77c2-b55b-2fc68542adcc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_EntityAddressAddressLine1_019e93dd-9df4-77c2-b55b-2fc68542adcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_019e93dd-9df4-768e-a6d7-951f20084c6c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_EntityAddressAddressLine2_019e93dd-9df4-768e-a6d7-951f20084c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019e93dd-9df4-7886-a272-ccd4bed3c4a2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_EntityAddressCityOrTown_019e93dd-9df4-7886-a272-ccd4bed3c4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019e93dd-9df4-7e13-81c5-b547b62ec59d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_EntityAddressStateOrProvince_019e93dd-9df4-7e13-81c5-b547b62ec59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019e93dd-9df4-7423-a8ed-bd21dd7d2cef" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_EntityAddressPostalZipCode_019e93dd-9df4-7423-a8ed-bd21dd7d2cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019e93dd-9df4-7bd7-b421-d6ffb2510c58" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_CityAreaCode_019e93dd-9df4-7bd7-b421-d6ffb2510c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019e93dd-9df4-7a23-a391-f962d23ed5e2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_LocalPhoneNumber_019e93dd-9df4-7a23-a391-f962d23ed5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_019e93dd-9df4-7c37-81e7-161b74c4c643" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_WrittenCommunications_019e93dd-9df4-7c37-81e7-161b74c4c643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_019e93dd-9df4-72b9-9c05-20dabfb7f33d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_SolicitingMaterial_019e93dd-9df4-72b9-9c05-20dabfb7f33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_019e93dd-9df4-77c0-aee9-a153052a83bb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_PreCommencementTenderOffer_019e93dd-9df4-77c0-aee9-a153052a83bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_019e93dd-9df4-72b2-8ef1-0ba577e68b54" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_019e93dd-9df4-72b2-8ef1-0ba577e68b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019e93dd-9df4-71ce-b118-f1f9184014c5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_Security12bTitle_019e93dd-9df4-71ce-b118-f1f9184014c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019e93dd-9df4-75be-916e-b5009b3a0370" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_TradingSymbol_019e93dd-9df4-75be-916e-b5009b3a0370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019e93dd-9df4-7e20-a73e-2ef879b152e7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_SecurityExchangeName_019e93dd-9df4-7e20-a73e-2ef879b152e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019e93dd-9df4-7e7a-8b36-ffa75adaf279" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_EntityEmergingGrowthCompany_019e93dd-9df4-7e7a-8b36-ffa75adaf279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019e93dd-9df4-75d4-b834-f5099f70fe07" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_EntityCentralIndexKey_019e93dd-9df4-75d4-b834-f5099f70fe07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019e93dd-9df4-7c11-84c0-e1e168dba77d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e93dd-9df4-70fd-ad91-e8c8cf7a2079" xlink:to="loc_dei_AmendmentFlag_019e93dd-9df4-7c11-84c0-e1e168dba77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 11, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 11,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NURIX THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-0838048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1600 Sierra Point Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">660-5320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NRIX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001549595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nrix-20260611.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nurixtx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="nrix-20260611.htm">nrix-20260611.htm</File>
    <File>nrix-20260611.xsd</File>
    <File>nrix-20260611_lab.xml</File>
    <File>nrix-20260611_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nrix-20260611.htm": {
   "nsprefix": "nrix",
   "nsuri": "http://www.nurixtx.com/20260611",
   "dts": {
    "inline": {
     "local": [
      "nrix-20260611.htm"
     ]
    },
    "schema": {
     "local": [
      "nrix-20260611.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "nrix-20260611_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nrix-20260611_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 7,
    "http://xbrl.sec.gov/dei/2025": 7
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 26
   },
   "report": {
    "R1": {
     "role": "http://www.nurixtx.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrix-20260611.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrix-20260611.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.nurixtx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001549595-26-000034-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001549595-26-000034-xbrl.zip
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M_Q#Q%>T:TMOXK)KZ6D#'DP^MD7B[R1G5.(!;VB!O&9QB25B3N$Q'Y#X=@36
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M:!:WAZ4#K)J>Z[7=HF_AW<ESO.M*&"QL/%-12><'YH*Y=\#. QJ/%/!]J\M
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MJ'4W$D":K<6,&LI_YT_ -H@ =G-C&4IM9(16+AD;P!#@&FDX ;HDSIT$=,A
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M,#(V,#8Q,5]L86(N>&UL4$L! A0#%     @ W%C+7"$U4\K_!0  ]C(  !4
M             ( !"C<  &YR:7@M,C R-C V,3%?<')E+GAM;%!+!08
.!0 % % !   \/0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>nrix-20260611_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nrix-20260611.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001549595</identifier>
        </entity>
        <period>
            <startDate>2026-06-11</startDate>
            <endDate>2026-06-11</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-20">0001549595</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-22">2026-06-11</dei:DocumentPeriodEndDate>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-23">1600 Sierra Point Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-24">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-25" xsi:nil="true"/>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-26">CA</dei:EntityAddressStateOrProvince>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="c-1" id="f-2">NURIX THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-4">001-39398</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-5">27-0838048</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-6">1600 Sierra Point Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-7">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-8">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-9">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-10">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-11">660-5320</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-12">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-13">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-14">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">NRIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-19">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
